← BackLantheus Holdings, Inc. · In Vitro & In Vivo Diagnostic SubstancesLNTH
Low riskNext report: Around Nov 5 (est.)
The short versionA high-quality, profitable business with steady sales. Institutions are adding.
Going well
- Profitable, keeps 15% of sales as profit
- Brings in more cash than it spends
- Buying back shares: share count down 3.2% in 3 years
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 4% to their holdings in the quarter ending June 2026 (239 bought, 172 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$99.93+0.1% that day
- Company value
- $6.5B
- Share price times all shares
- Price vs profit (P/E)
- 24.2x
- You pay about $24 for each $1 of yearly profit
- Price vs sales
- 4.2x
- Company value is 4.2 times a year of sales
- Cash vs value
- 9%
- Cash as a share of company value
- Debt vs value
- 0%
- Debt as a share of company value
From LNTH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$388.2M+2.7% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.6B, up 2.3% from the 12 months before. Over 5 years, sales grew about 35% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.21.4%
- PassDebt under half of equityNot relying on borrowed money.0.00x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.15.2%
- MissProfitable every yearSteady profits, not one good year.8 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$390.1M
- PassShare count not growingNot diluting owners. Falling means buybacks.-3.2% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.61.1%
- Revenue
- $1.5B
- +0.5% vs prior year
- 5-year growth
- +35.3%/yr
- revenue, per year
- Total debt
- $738K
- 0.00x equity
- Current ratio
- 2.70x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $388.2M
- +2.7% YoY
- EPS
- $1.11
- vs $1.12
- Op. margin
- 25.8%
- +2.5 pts
- Gross margin
- 62.3%
- -1.5 pts
- Free cash flow
- $92.2M
- Share count
- -4.0%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
29/ 100
- This week
- 1
- Normal week
- 2.5
- vs normal
- 0.4x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+4.0%Institutions added 4.0% to their holdings. 239 bought, 172 sold. 2 quarters of net buying in a row.
Shares held by institutions76.0M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-1.6%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.4x · $570.4M debtShares outstandingLatest reported
65MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 7
- Results filedFeb 26
- Results filedNov 6, 2025
- Results filedAug 6, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
SoldLantheus Alpha Therapy, LLC10% owner
247,932 shares at $3.13 avg ($3.11 to $3.15) · $777K
- -2% of holdings
- Now owns 11,273,364 shares
- Not a pre-planned sale
- 2 transactions
- Filed 4 days after trade
- Joint filing with 1 other
SoldLantheus Alpha Therapy, LLC10% owner
42,129 shares at $3.11 · $131K
- -0% of holdings
- Now owns 11,521,296 shares
- Not a pre-planned sale
- Filed 2 days after trade
- Joint filing with 1 other
SoldLantheus Holdings, Inc.10% owner
35,769 shares at $3.12 · $112K
- -0% of holdings
- Now owns 11,563,425 shares
- Not a pre-planned sale
- Filed 2 days after trade